Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AgenusAGEN -2.32%43 Debt-to-EBITDA is 0.67 as of Jun. 2026. GuruFocus rates AGEN with a GF Score™ of 43/100 and a GF Value™ of $3.78 (Significantly Overvalued). The stock has 12 warning signs investors should review. Among 302 Biotechnology companies, Agenus ranks better than 73.18% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Agenus's Debt-to-EBITDA or its related term are showing as below:
AGEN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.7 Med: -0.49 Max: 1.33
Current: 0.26
During the past 13 years, the highest Debt-to-EBITDA Ratio of Agenus was 1.33. The lowest was -1.70. And the median was -0.49.
AGEN's Debt-to-EBITDA is ranked better than 73.18% of 302
companies
in the Biotechnology industry
Industry Median: 1.29
vs AGEN: 0.26
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Agenus Debt-to-EBITDA Related Terms
Agenus Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Agenus's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AGEN vs FULC, IRD, TTRX: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Agenus's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agenus Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agenus's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Agenus's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Agenus (AGEN) has a Debt-to-EBITDA of 0.67 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Agenus. According to the industry distribution chart, Agenus ranks #81 out of 302 companies in the Biotechnology industry, placing it in the top 26.8%.
Is Agenus' Debt-to-EBITDA too high?
Agenus' current Debt-to-EBITDA is 0.67. The Biotechnology industry median Debt-to-EBITDA is 1.29. Agenus' value of 0.67 is 48.1% below this industry median. Based on the distribution chart, Agenus ranks #81 out of 302 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Agenus has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Agenus' Debt-to-EBITDA compare to FULC and IRD?
According to the Biotechnology industry distribution chart, Agenus ranks #81 out of 302 companies for Debt-to-EBITDA. This puts Agenus in the upper half of its industry. The industry median Debt-to-EBITDA is 1.29. Agenus' value of 0.67 is 48.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.29, based on 302 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agenus's current Debt-to-EBITDA of 0.67 is 48.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Agenus. For the Biotechnology industry, the median Debt-to-EBITDA is 1.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agenus's current Debt-to-EBITDA is 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agenus stock overvalued right now?
Based on GuruFocus' analysis, Agenus (AGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.78, compared to a current price of $7.16 — trading 89.3% above its estimated fair value. The current Debt-to-EBITDA is 0.67 and 48.1% below the Biotechnology industry median of 1.29. Agenus' overall GF Score™ is 43/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Agenus (AGEN), the current Debt-to-EBITDA is 0.67 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agenus (AGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Agenus stock appears to be overvalued.
The current stock price of $7.16 is trading 89.3% above its estimated GF Value™ of $3.78.
GuruFocus considers Agenus to be Significantly Overvalued.
Key valuation signals for AGEN:
Debt-to-EBITDA: 0.67
GF Value™: $3.78 vs. price of $7.16 (89.3% above fair value)
Industry Position: 48.1% below the Biotechnology median (#81 of 302)
No single metric tells the full story. See the AGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
43GF Score
Get the complete analysis for AGEN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGEN has been successfully added to your 
